{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:37:26Z","timestamp":1794580646568,"version":"4.9.1"},"reference-count":20,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Patients at risk for progression from myeloid precursor states (idiopathic cytopenia of undetermined significance [ICUS] and clonal cytopenia of undetermined significance [CCUS]) to myelodysplastic syndrome (MDS) are not well defined. Epidemiologic risk factors, clonal changes for MDS development, and evolution from one MDS state to another were available in the MDS Natural History Study (NHS), a prospective cohort enrolled at diverse US sites. Extensive clinical data and biospecimens were collected at baseline and follow-up. A total of 1177 (56%) individuals with MDS or MDS-related precursor conditions (ICUS\/idiopathic dysplasia of undetermined significance [IDUS], CCUS, and MDS\/myeloproliferative neoplasm overlap) were enrolled and diagnosed in the MDS NHS. The median age was 74 years, with 89% aged \u226560 years, and most were male patients. Median follow-up time was 1.6 years and was similar among ICUS\/IDUS, CCUS, and MDS. During follow-up period, 68% of participants terminated the study, 35% died, and 38% had disease progression. Using a refined clinical definition of progression, the greatest proportion of progression was observed among higher-risk-MDS (116 [73%]), followed by lower-risk-MDS (170 [52%]); fewer progression events were observed among participants with CCUS (65 [22%]) and ICUS\/IDUS (46 [17%]). Predictors of progression are delineated, including female sex, higher quantity of mutations, the presence of TP53 mutation, and poor\/very poor cytogenetic score. Based on these prospective data, guidelines for clinical management including monitoring and surveillance are outlined. The MDS NHS provides real-world data to illustrate how clinical and genotypic differences inform the classification, disease course, and approach to therapy, with informed monitoring guidelines for patients. This trial was registered at www.ClinicalTrials.gov as NCT02775383.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018770","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T20:00:01Z","timestamp":1770840001000},"page":"2743-2753","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study"],"prefix":"10.1182","volume":"10","author":[{"given":"Amy E.","family":"DeZern","sequence":"first","affiliation":[{"name":"1Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7744-8490","authenticated-orcid":false,"given":"Nancy","family":"Gillis","sequence":"additional","affiliation":[{"name":"2H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5489-014X","authenticated-orcid":false,"given":"Michael","family":"Otterstatter","sequence":"additional","affiliation":[{"name":"3The Emmes Company, LLC, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Abel","sequence":"additional","affiliation":[{"name":"4Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[{"name":"2H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4426-9023","authenticated-orcid":false,"given":"H. Joachim","family":"Deeg","sequence":"additional","affiliation":[{"name":"5Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tareq","family":"Al Baghdadi","sequence":"additional","affiliation":[{"name":"6Michigan Cancer Research Consortium, Ypsilanti, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Liu","sequence":"additional","affiliation":[{"name":"7Illinois CancerCare, Peoria, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoer","family":"Xie","sequence":"additional","affiliation":[{"name":"2H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-1458","authenticated-orcid":false,"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"2H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Moscinski","sequence":"additional","affiliation":[{"name":"2H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4723-6307","authenticated-orcid":false,"given":"Steven","family":"Kroft","sequence":"additional","affiliation":[{"name":"8Department of Pathology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Harrington","sequence":"additional","affiliation":[{"name":"8Department of Pathology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Foran","sequence":"additional","affiliation":[{"name":"9Mayo Clinic Comprehensive Cancer Center Hematology, Mayo Clinic Florida, Jacksonville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5269","authenticated-orcid":false,"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[{"name":"2H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Starczynowski","sequence":"additional","affiliation":[{"name":"10Advanced Leukemia Therapies and Research Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Gore","sequence":"additional","affiliation":[{"name":"11Cancer Therapy Evaluation Program Investigational Drug Branch, National Cancer Institute Division of Cancer Treatment and Diagnosis, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Saber","sequence":"additional","affiliation":[{"name":"12Division of Hematology Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5603-4598","authenticated-orcid":false,"given":"Rafael","family":"Bejar","sequence":"additional","affiliation":[{"name":"13Divisions of Hematology-Oncology and Bone Marrow Transplantation, University of California San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9822-806X","authenticated-orcid":false,"given":"R. C.","family":"Lindsley","sequence":"additional","affiliation":[{"name":"4Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3667-9898","authenticated-orcid":false,"given":"Seth","family":"Sherman","sequence":"additional","affiliation":[{"name":"3The Emmes Company, LLC, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Lee","sequence":"additional","affiliation":[{"name":"14Division of Cancer Prevention, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"DiFronzo","sequence":"additional","affiliation":[{"name":"15Blood Epidemiology and Clinical Therapeutics, National Heart, Lung, and Blood Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Walter","sequence":"additional","affiliation":[{"name":"16Department of Oncology, Washington University School of Medicine, St Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-6524","authenticated-orcid":false,"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[{"name":"17Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"3","key":"2026042809474879500_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/PPO.0000000000000665","article-title":"Epidemiology and pathogenesis of myelodysplastic syndrome","volume":"29","author":"Rotter","year":"2023","journal-title":"Cancer J"},{"key":"2026042809474879500_bib2","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1200\/EDBK_239083","article-title":"CHIP, CCUS, and other acronyms: definition, implications, and impact on practice","volume":"39","author":"DeZern","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"20","key":"2026042809474879500_bib3","doi-asserted-by":"crossref","first-page":"5148","DOI":"10.1182\/bloodadvances.2025017215","article-title":"Ethical considerations for hematologic precursor conditions","volume":"9","author":"Blackstone","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"2026042809474879500_bib4","doi-asserted-by":"crossref","first-page":"e659","DOI":"10.1016\/S2352-3026(24)00142-X","article-title":"Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial","volume":"11","author":"Diez-Campelo","year":"2024","journal-title":"Lancet Haematol"},{"issue":"12","key":"2026042809474879500_bib5","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2026042809474879500_bib6","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International Scoring System for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"issue":"33","key":"2026042809474879500_bib7","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.20.02810","article-title":"Personalized prediction model to risk stratify patients with myelodysplastic syndromes","volume":"39","author":"Nazha","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026042809474879500_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"13","key":"2026042809474879500_bib9","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1080\/10428194.2019.1616186","article-title":"The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes","volume":"60","author":"Sekeres","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"2026042809474879500_bib10","doi-asserted-by":"crossref","first-page":"6120","DOI":"10.1182\/bloodadvances.2023010061","article-title":"Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies","volume":"7","author":"Gorak","year":"2023","journal-title":"Blood Adv"},{"issue":"7","key":"2026042809474879500_bib11","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"14","key":"2026042809474879500_bib12","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1182\/bloodadvances.2022008578","article-title":"Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions","volume":"7","author":"DeZern","year":"2023","journal-title":"Blood Adv"},{"issue":"17","key":"2026042809474879500_bib13","first-page":"2047","article-title":"Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2026042809474879500_bib14","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood-2018-06-857102","article-title":"Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"issue":"446","key":"2026042809474879500_bib15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"25","key":"2026042809474879500_bib16","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2026042809474879500_bib17","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.2021011323","article-title":"Relationship between clone metrics and clinical outcome in clonal cytopenia","volume":"138","author":"Galli","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2026042809474879500_bib18","doi-asserted-by":"crossref","first-page":"100026","DOI":"10.1016\/j.bneo.2024.100026","article-title":"Correlation between peripheral blood and bone marrow mutations among patients with MDS from the National MDS Study","volume":"1","author":"DeZern","year":"2024","journal-title":"Blood Neoplasia"},{"issue":"7","key":"2026042809474879500_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"4","key":"2026042809474879500_bib20","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41375-020-0997-4","article-title":"Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)","volume":"35","author":"Yun","year":"2021","journal-title":"Leukemia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/8\/2743\/2514216\/blooda_adv-2025-018770-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/8\/2743\/2514216\/blooda_adv-2025-018770-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:47:53Z","timestamp":1777384073000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/8\/2743\/566567\/A-novel-approach-to-defining-progression-in-MDS"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,4,28]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018770","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,28]]},"published":{"date-parts":[[2026,4,17]]}}}